213 related articles for article (PubMed ID: 27538897)
1. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
Mueller D; Krug S; Majumder M; Rinke A; Gress TM
BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
[TBL] [Abstract][Full Text] [Related]
2. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
5. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
[TBL] [Abstract][Full Text] [Related]
8. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial.
Krug S; Kegel T; Gress TM; Rinke A; Apostolidis L; Jann H; König A; Hörsch D; Schrader J; Ettrich TJ; Richter M; Steighardt J; Michl P
BMC Cancer; 2021 Nov; 21(1):1206. PubMed ID: 34772353
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
11. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
16. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Claringbold PG; Turner JH
Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
[TBL] [Abstract][Full Text] [Related]
18. Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population.
Chiu HY; Lin LY; Chou WC; Fang WL; Shyr YM; Yeh YC; Mu-Hsin Chang P; Chen MH; Hung YP; Chao Y; Chien SH; Chen MH
J Chin Med Assoc; 2018 May; 81(5):423-428. PubMed ID: 29287706
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
Bajetta E; Rimassa L; Carnaghi C; Seregni E; Ferrari L; Di Bartolomeo M; Regalia E; Cassata A; Procopio G; Mariani L
Cancer; 1998 Jul; 83(2):372-8. PubMed ID: 9669822
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Olsen IH; Sørensen JB; Federspiel B; Kjaer A; Hansen CP; Knigge U; Langer SW
ScientificWorldJournal; 2012; 2012():170496. PubMed ID: 22973169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]